Bright Minds is Unaware of Any Material Changes

Group 1 - Bright Minds Biosciences Inc. has confirmed that its management is unaware of any material changes in operations that would explain the recent increase in market activity [1] - The company focuses on developing novel treatments for neuropsychiatric disorders, epilepsy, and pain, utilizing next-generation serotonin agonists [2] - Bright Minds aims to create drugs that retain the therapeutic benefits of psychedelic and serotonergic compounds while minimizing side effects, positioning them as superior to first-generation drugs [2] Group 2 - The Canadian Securities Exchange has neither approved nor disapproved the contents of the news release [3]